

HYCOR Elects New Member to Board of Directors

Sysmex America President and CEO, John Kershaw, to Provide International Market Expertise

GARDEN GROVE, CA (July 19, 2012) - HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets, together with owner Linden Capital Partners, today announced the appointment of John Kershaw, President and CEO of Sysmex America, Inc., a global leader in the design and development of clinical diagnostic hematology, coagulation and urinalysis equipment and information management systems, to its Board of Directors as part of its global growth strategy.

"John brings extensive international experience in diagnostics from a market leading company and we look forward to his contributions as a member of the HYCOR team," said Richard Novak, Chairman of HYCOR's Board of Directors, and Operating Partner at Linden. "His insights and relationships, developed throughout his career in Europe and Asia, will have great impact in helping to guide HYCOR in the years ahead as we continue to grow internationally."

Mr. Kershaw joins HYCOR's Board of Directors with more than 16 years of domestic and international experience and leadership with Sysmex Corporation where he held several senior management and executive positions, including Executive Vice President of Sysmex Europe and Chief Operating Officer, Managing Director, and a Board Member of Sysmex's U.S. headquarters. In 2009, Kershaw was elevated to the position of President and CEO of Sysmex America, Inc. He is a fellow of the Association of Medical Technologists in the United Kingdom and serves as Sysmex's representative member of AdvaMed.

As a Director at HYCOR, Mr. Kershaw will support the senior management team in a variety of capacities with a particular focus on international market expansion. He joins fellow Directors Dr. Vijay Aggarwal, formerly of Quest Diagnostics, and Dr. James Koziarz, formerly of Abbott Diagnostics, as an outside Director serving HYCOR.

"The HYCOR team is pleased to have someone of John's caliber join our diverse and talented group of advisors," said HYCOR CEO Dick Aderman, formerly of Roche Diagnostics and Boehringer Mannheim. "We are certain that he will influence key areas of our business, specifically in helping drive our global strategy during this important time of growth for the company."

About HYCOR Biomedical, Inc.

Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.hycorbiomedical.com.

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is comprised of three elements: i)

healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic corporate relationships. Linden invests in middle market companies across the healthcare spectrum, including medical products, healthcare services, and distribution. For additional information about Linden, please visit www.lindenllc.com.